{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:11:28Z","timestamp":1761052288636,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"crossref","award":["NT\/12392-4","00023736"],"award-info":[{"award-number":["NT\/12392-4","00023736"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.bcmd.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T21:30:23Z","timestamp":1457559023000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Simplifying procedure for prediction of resistance risk in CML patients \u2014 Test of sensitivity to TKI ex vivo"],"prefix":"10.1016","volume":"58","author":[{"given":"Mark\u00e9ta","family":"\u017d\u00e1\u010dkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Mach\u00e1\u010dkov\u00e1-Lopotov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Ondr\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate\u0159ina","family":"Ku\u017eelov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Klamov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Moravcov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.bcmd.2016.03.005_bb0005","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcmd.2016.03.005_bb0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/leu.2011.217","article-title":"Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy","volume":"26","author":"Shami","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.bcmd.2016.03.005_bb0020","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BRC-ABL mutation really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0025","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2006.09.9499","article-title":"Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia","volume":"25","author":"White","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2016.03.005_bb0030","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.3747\/co.v18i2.391","article-title":"Monitoring response and resistance to treatment in chronic myeloid leukemia","volume":"18","author":"Assouline","year":"2011","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bcmd.2016.03.005_bb0035","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1634\/theoncologist.2010-0388","article-title":"Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC?","volume":"16","author":"Soverini","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0040","doi-asserted-by":"crossref","first-page":"S-1","DOI":"10.6004\/jnccn.2012.0184","article-title":"Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure","volume":"10","author":"Cortes","year":"2012","journal-title":"J. Natl. Compr. cancer Netw."},{"key":"10.1016\/j.bcmd.2016.03.005_bb0045","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","article-title":"Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance","volume":"27","author":"Zhang","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bcmd.2016.03.005_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5507\/bp.2011.059","article-title":"A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change","volume":"157","author":"Rohon","year":"2013","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"issue":"7","key":"10.1016\/j.bcmd.2016.03.005_bb0055","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3109\/10428194.2012.682314","article-title":"Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"53","author":"Devendra","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.bcmd.2016.03.005_bb0060","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cncr.22046","article-title":"Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy","volume":"107","author":"Alimena","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","article-title":"Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"107","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcmd.2016.03.005_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev."},{"issue":"7","key":"10.1016\/j.bcmd.2016.03.005_bb0075","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3109\/10428194.2013.845883","article-title":"Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia","volume":"55","author":"Jabbour","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/asheducation.V2006.1.219.0010219","article-title":"Defining and managing imatinib resistance","author":"Mauro","year":"2006","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0085","series-title":"Chronic Myeloid Leukemia: From Daily Management to Complicated Issues","first-page":"79","article-title":"Secondary resistance to tyrosine kinase inhibitors: focus on molecular mechanisms other than BCR-ABL overexpression and mutations","author":"Tereza","year":"2014"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0090","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bcmd.2016.03.005_bb0095","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23338","article-title":"Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors","volume":"87","author":"Redaelli","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.bcmd.2016.03.005_bb0100","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcmd.2016.03.005_bb0105","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1200\/JCO.2009.26.4945","article-title":"Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia","volume":"28","author":"Laneuville","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bcmd.2016.03.005_bb0110","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bcmd.2016.03.005_bb0115","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V84.6.1731.1731","article-title":"Tyrosine phosphorylation of CRKL in Philadelphia+leukemia","volume":"84","author":"ten Hoeve","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0120","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"White","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcmd.2016.03.005_bb0125","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.leukres.2009.09.009","article-title":"Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation","volume":"34","author":"Faber","year":"2010","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.bcmd.2016.03.005_bb0130","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.leukres.2011.01.012","article-title":"Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylation","volume":"35","author":"Shibata","year":"2011","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.bcmd.2016.03.005_bb0135","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3109\/10428194.2012.656104","article-title":"BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL\/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response","volume":"53","author":"Simara","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0140","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3324\/haematol.2008.003715","article-title":"The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib","volume":"94","author":"Khorashad","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0145","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.leu.2404189","article-title":"BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry","volume":"20","author":"Hamilton","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bcmd.2016.03.005_bb0150","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0155","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2016.03.005_bb0160","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood.V116.21.2747.2747","article-title":"In vitro sensitivity to tyrosine kinase inhibitors is one of possible predictive parameters for therapy switch in patients with chronic myeloid leukemia","volume":"116","author":"Zackova","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcmd.2016.03.005_bb0165","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bcmd.2012.11.002","article-title":"Hsp90 - a potential prognostic marker in CML","volume":"50","author":"Zackova","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.03.005_bb0170","series-title":"Culture of animal cells: a manual of basic technique","first-page":"117","author":"Freshney","year":"1987"},{"issue":"14","key":"10.1016\/j.bcmd.2016.03.005_bb0175","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1096\/fj.02-0392fje","article-title":"Degradation of cellular mRNA is a general early apoptosis-induced event","volume":"16","author":"Del Prete","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.bcmd.2016.03.005_bb0180","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V84.9.2912.2912","article-title":"Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells","volume":"84","author":"Nichols","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0185","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/gcc.20377","article-title":"Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2","volume":"45","author":"Patel","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.bcmd.2016.03.005_bb0190","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","article-title":"Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction","volume":"162","author":"Chomczynski","year":"1987","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bcmd.2016.03.005_bb0195","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.leukres.2006.07.021","article-title":"The effect of total-ABL GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR","volume":"31","author":"Rulcov\u00e1","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2016.03.005_bb0200","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2141.2001.02912.x","article-title":"Fluorescent 5\u2032-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias","volume":"114","author":"Kreuzer","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.bcmd.2016.03.005_bb0205","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cncr.20457","article-title":"Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation","volume":"101","author":"Cilloni","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bcmd.2016.03.005_bb0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4149\/neo_2009_05_393","article-title":"WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance","volume":"56","author":"Otahalova","year":"2009","journal-title":"Neoplasma"},{"issue":"7","key":"10.1016\/j.bcmd.2016.03.005_bb0215","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.leukres.2011.03.029","article-title":"MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?","volume":"35","author":"Lopotov\u00e1","year":"2011","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.bcmd.2016.03.005_bb0220","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0225","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0230","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.bcmd.2016.03.005_bb0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0165-4608(87)90131-2","article-title":"The karyotype of blastic crisis","volume":"26","author":"Alimena","year":"1987","journal-title":"Cancer Genet. Cytogenet."},{"issue":"1\u20132","key":"10.1016\/j.bcmd.2016.03.005_bb0240","first-page":"83","article-title":"Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature","volume":"38","author":"Hern\u00e1ndez-Boluda","year":"2000","journal-title":"Leuk. Lymphoma"},{"issue":"26","key":"10.1016\/j.bcmd.2016.03.005_bb0245","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung (SAKK) and the German CML Study Group. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bcmd.2016.03.005_bb0250","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcmd.2016.03.005_bb0285","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.bcmd.2016.03.005_bb0290","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3months may predict both response and event-free survival at 24months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcmd.2016.03.005_bb0295","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bcmd.2016.03.005_bb0300","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.005_bb0305","first-page":"790","article-title":"Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications Am","volume":"88","author":"Pavlik","year":"2013","journal-title":"J. Hematol."},{"issue":"1","key":"10.1016\/j.bcmd.2016.03.005_bb0310","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cas.12321","article-title":"European treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients","volume":"105","author":"Yamamoto","year":"2014","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.bcmd.2016.03.005_bb0315","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcmd.2016.03.005_bb0320","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/ijlh.12258","article-title":"Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors","volume":"37","author":"Krupkova","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"issue":"2","key":"10.1016\/j.bcmd.2016.03.005_bb0325","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5507\/bp.2011.030","article-title":"Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: implications for treatment strategy","volume":"155","author":"Rohon","year":"2011","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:32:27Z","timestamp":1761049947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616300195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":59,"alternative-id":["S1079979616300195"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.03.005","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simplifying procedure for prediction of resistance risk in CML patients \u2014 Test of sensitivity to TKI ex vivo","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}